References
- Juweid ME, Stroobants S, Hoekstra OS, et al Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571–578.
- Cheson BD, Pfistner B, Juweid ME, et al Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
- Hoh CK, Glaspy J, Rosen P, et al Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997;38:343–348.
- Jerusalem G, Beguin Y, Najjar F, et al Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001;12:825–830.
- Schöder H, Meta J, Yap C, et al Effect of whole-body (18) F-FDG PET imaging on clinical staging andmanagement of patients with malignant lymphoma. J Nucl Med 2001;42:1139–1143.
- Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood 2008;111:504–516.
- Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603–609.
- Szczuraszek K, Mazur G, Jeleń M, Dziegiel P, Surowiak P, Zabel M. Prognostic significance of Ki-67 antigen expression in non-Hodgkin's lymphomas. Anticancer Res 2008;28:1113–1138.
- Determann O, Hoster E, Ott G, et al Ki-67 predicts outcome in advanced-stage mantle-cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385–2387.
- Kim SJ, Kim BS, Choi CW, et al Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol 2007;18:1382–1387.
- Chen W, Cloughesy T, Kamdar N, et al Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 2005;46:945–952.
- Kitagawa Y, Sano K, Nishizawa S, et al FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging 2003;30:63–71.
- Vesselle H, Schmidt RA, Pugsley JM, et al Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837–3844.
- Folpe AL, Lyles RH, Sprouse JT, Conrad EU III, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6:1279–1287.
- Rodriguez M, Rehn S, Ahlström H, Sundström C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995;36:1790–1796.
- Lapela M, Leskinen S, Minn HR, et al Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995;86:3522–3527.
- Wong CY, Thie J, Parling-Lynch KJ, et al Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas. J Nucl Med 2005;46:1659–1663.
- Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol 2005;23:4577–4780.
- Schöder H, Noy A, Gönen M, et al Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005;23:4643–4651.
- Swerdlow SH, Campo E, Harris NL, et al WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.